Suboptimal Rate of Initial BRC-ABL1 Decline on Imatinib Signals Change in Inhibitor Warranted
Patients with high Sokal risk treated with imatinib have a higher rate of treatment failure and poorer molecular response.
ASH 2014
Age, dPCR Analysis Predict Risk of Relapse in Leukemia Following Imatinib Discontinuation
Age less than 45 years of age and digital-PCR (dPCR) positivity are significantly associated with relapses in chronic myeloid leukemia (CML).
Inotuzumab Ozogamicin + MiniHCVD: New Standard of Care for Frontline Leukemia in Older Patients?
Combining inotuzumab ozogamicin with low-intensity chemotherapy achieved results better in newly diagnosed B-cell acute lymphoblastic leukemia (ALL).
Nilotinib Plus Chemotherapy Effective for First-Line Treatment of Acute Lymphoblastic Leukemia (ALL)
Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1-positive acute lymphocytic leukemia (ALL).
No Intensified Peg-Asparaginase Benefit in Standard Risk Acute Lymphoblastic Leukemia (ALL)
About 35% of standard risk B-acute lymphocytic leukemia (B-ALL) patients meet low risk criteria and are almost sure to be cured.
Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression
Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted in better survival.
Dasatinib Remains Effective In Imatinib-Resistant, -Intolerant Chronic-Phase Leukemia
Dasatinib continues to demonstrate durable efficacy and benefit during a 7-year follow-up for chronic-phase chronic myeloid leukemia (CML-CP).
Autologous Stem Cell Transplantation: ‘Standard of Care’ for HIV-Associated Lymphoma?
Autologous hematopoietic stem cell transplantation (AHCT) should be considered standard of care for HIV-associated lymphoma.
Tosedostat Plus Cytarabine or Decitabine Induces Remission in Older Patients with AML/MDS
Tosedostat with cytarabine or decitabine induced complete remission in acute myeloid leukemia (AML)/high-risk myelodysplastic syndrome (MDS).
Pacritinib’s Lack of Myelosuppression May Be Due to Lack of JAK1, IRAK1 Inhibition
Profile of pacritinib suggests potential role in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2014
Loading... 
Loading...